Immunocore Holdings Plc ((IMCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Immunocore Holdings Plc is conducting a Phase 1/2 study titled ‘A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers’. The study aims to evaluate the safety and efficacy of IMC-R117C in treating advanced PIWIL1-positive cancers, which could potentially lead to new treatment options for these conditions.
Intervention/Treatment: The study tests IMC-R117C, a bispecific protein designed to target cancer cells. It is administered as an intravenous infusion, both as a standalone treatment and in combination with other therapies such as chemotherapy, antiangiogenic agents, kinase inhibitors, and monoclonal antibodies.
Study Design: This interventional study is non-randomized with a sequential assignment model. It involves multiple experimental arms testing different combinations of IMC-R117C and other treatments, alongside a control arm receiving standard care. The primary goal is treatment-focused, with no masking involved.
Study Timeline: The study began on February 5, 2025, with the latest update submitted on July 21, 2025. These dates are crucial as they mark the study’s progression and ongoing recruitment status, indicating active research and potential upcoming results.
Market Implications: This study update could positively influence Immunocore’s stock performance by showcasing its innovative approach to cancer treatment. Successful outcomes may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.